Neurologic Diseases
Also known as: Nervous system diseases
Methodology & AI Transparency ⓘ
Neurologic Diseases Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: The brain, spinal cord, and nerves make up the nervous system.
- 2 Real-world patient consensus: Diagnostic registry G62.9: Neurologic Diseases is managed within Brain & Neurology (aka Nervous system diseases).
- 3 Typical cash cost range: Workup highlights for Neurologic Diseases (G62.9): neurorehabilitation tracking [Neurologic Diseases G62.9].
- 4 Top reported side effects / signs: Objective lab/clinical target for Neurologic Diseases: Serum Vitamin B12 in Neurologic Diseases (G62.9: & Methylmalonic Acid) (B12 > 500 pg/mL; MMA < 240 nmol/L (G62.9)) and Carotid Duplex / in Neurologic Diseases (G62.9: Cerebral Perfusion).
Ask our AI Specialists anything about Neurologic Diseases
What Is Neurologic Diseases?
The brain, spinal cord, and nerves make up the nervous system. Together they control all the workings of the body. When something goes wrong with a part of your nervous system, you can have trouble moving, speaking, swallowing, breathing, or learning. You can also have problems with your memory, senses, or mood. There are more than 600 neurologic diseases.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in brain & neurology, Neurologic Diseases (G62.9) involves blood-brain barrier neuroinflammation [Neurologic Diseases G62.9]. Cross-referenced with NIH MeSH (Nervous System Diseases), progression correlates with shifts in Serum Vitamin B12 in Neurologic Diseases (G62.9: & Methylmalonic Acid) (B12 > 500 pg/mL; MMA < 240 nmol/L (G62.9)).
Common Symptoms & Clinical Signs
- • Diseases caused by faulty genes, such as Huntington's disease and muscular dystrophy
- • Problems with the way the nervous system develops, such as spina bifida
- • Presentation of Neurologic Diseases (G62.9): episodic vertigo, imbalance, in Neurologic Diseases (G62.9: coordination drift, or)
- • Secondary Neurologic Diseases clinical sign: numbness, paresthesia, or in Neurologic Diseases (G62.9: visual field/speech changes)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Neurologic Diseases Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G62.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Neurology, Stroke & Movement Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Serum Vitamin B12 in Neurologic Diseases (G62.9: & Methylmalonic Acid) | B12 > 500 pg/mL; MMA < 240 nmol/L (G62.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Carotid Duplex / in Neurologic Diseases (G62.9: Cerebral Perfusion) | No hemodynamically significant stenosis (G62.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: HbA1c & Blood in Neurologic Diseases (G62.9: Pressure Neuro-Targets) | BP < 120/75 mmHg; HbA1c < 5.7% (G62.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Neurologic Diseases
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Glycopyrrolate Oral Solution Glycopyrrolate Oral Solution Generic • RxCUI 999961 | Anticholinergic | 90% | $0.1689 | $ 15.34 /mo |
| Tividenofusp Alfa-Eknm Avlayah • RxCUI 2740019 | Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme | 75% | $2.9300 | $ 127.17 /mo |
| Mitoxantrone Mitoxantrone Generic • RxCUI 197989 | Topoisomerase Inhibitor | 93% | $0.3500 | $ 22.68 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Neurologic Diseases)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy and quality-of-life improvements with fremanezumab treatment in patients: What a 838-Participant Study Found Fremanezumab reduced days with neurological symptoms, effectively prevented migraine, and improved quality of life in patients with migraine with associated neurological dysfunction, including. European journal of neurology • 2022-07-15 • Phase III Randomized Trial | N = 838 | 93/100 | PMID 35302681 ↗ |
| Can This Approach Help? Inside the Latest Research on Siponimod: Disentangling disability and relapses in secondary progressive By controlling the confounding impact of on-study relapses on confirmed disability progression, these statistical approaches provide a methodological framework to assess treatment effects on disability progression in relapsing... Multiple sclerosis (Houndmills, Basingstoke, England) • 2021-09-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33205682 ↗ |
| Can This Approach Help? Inside the Latest Research on Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve D/C/F/TAF may be a suitable treatment option for individuals with HIV-1 and NPCs. HIV medicine • 2023-03-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 36912173 ↗ |
| Can This Approach Help? Inside the Latest Research on An exposure-response analysis of ponesimod clinical efficacy in a randomized No significant baseline covariates affected the ponesimod effects and, consequently, dosage adjustments are not warranted by these analyses. CPT: pharmacometrics & systems pharmacology • 2022-10-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 36047474 ↗ |
| Can This Approach Help? Inside the Latest Research on Early Neurologic Deterioration and Efficacy of Dual Antiplatelet in Anterior Our study demonstrated END was higher in acute mild-to-moderate ischemic stroke with anterior circulation, who derived more benefit from clopidogrel plus aspirin than aspirin alone. Journal of the American Heart Association • 2025-02-04 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 39846303 ↗ |
Neurologic Diseases Patient Community & “People Like Me” Threads
Filter Neurologic Diseases community threads and patient logs by age, biological sex, dosage, and treatment duration.